A Pilot Study (Phase I/II) Testing the Immunologic Activity and Safety of AGS-004, an Autologous HIV Immunotherapeutic, in HIV-Infected Adults on HAART [highly active antiretroviral therapy].

Trial Profile

A Pilot Study (Phase I/II) Testing the Immunologic Activity and Safety of AGS-004, an Autologous HIV Immunotherapeutic, in HIV-Infected Adults on HAART [highly active antiretroviral therapy].

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2014

At a glance

  • Drugs AGS 004; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 05 Mar 2010 Positive results have been published in the journal Clinical Immunology according to an Argos Therapeutics media release.
    • 28 Jan 2009 Actual patient number changed from 9 to 10 as reported by ClinicalTrials.gov.
    • 06 Aug 2008 Status change from in progress to completed, according to an Argos Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top